Clinical Trials on Stage IA Fallopian Tube Cancer

Total 4280 results

University of Southern California
National Cancer Institute (NCI)

Terminated

High-Intensity Interval Training for Stage I-III Breast Cancer Patients

Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer

United States
Roswell Park Cancer Institute

Completed

Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Clear Cell Adenocarcinoma | Ovarian Mucinous Adenocarcinoma | Fallopian Tube Clear Cell Adenocarcinoma | Fallopian Tube Endometrioid Adenocarcinoma and other conditions

United States
University of Colorado, Denver
ImmunoGen, Inc.

Recruiting

An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib

Fallopian Tube Cancer | Peritoneal Cancer | Ovary Cancer

United States
Masonic Cancer Center, University of Minnesota

Completed

Intraperitoneal Delivery of Adaptive Natural Killer (NK) Cells (FATE-NK100) With Intraperitoneal Int

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Primary Peritoneal Cancer

United States
National Cheng-Kung University Hospital

Completed

Trial of Trientine Plus Pegylated Liposomal Doxorubicin and Carboplatin in Epithelial Ovarian Cancer (Trientine)

Fallopian Tube Cancer | Peritoneal Carcinoma | Ovarian Neoplasms Malignant (Excl Germ Cell)
Dana-Farber Cancer Institute
Massachusetts General Hospital; Brigham and Women's Hospital

Completed

Carboplatin and Pemetrexed in Recurrent Platinum Sensitive Ovarian Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cancer

United States
Southeastern Gynecologic Oncology
Celgene Corporation

Completed

Abraxane Plus Carboplatin for Recurrent Platinum-Sensitive Ovarian Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cancer

United States
CanariaBio Inc.
Veristat, LLC

Active, not recruiting

A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.

Peritoneal Cancer | Recurrent Ovarian Cancer | Recurrent Fallopian Tube Cancer | Recurrent Epithelial Cancer of Ovary | Recurrent Epithelial Ovarian Cancer | Recurrent Carcinoma of Ovary | Adenocarcinoma of Ovary

United States
Case Comprehensive Cancer Center
National Institute on Minority Health and Health Disparities (NIMHD)

Completed

Attitudes, Beliefs, and Preferences of Older Stage I-III Breast Cancer Survivors Towards Physical Activity

Cancer Survivor | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer

United States
Northwestern University
National Cancer Institute (NCI); Ipsen Biopharmaceuticals

Completed

Irinotecan Liposome and Bevacizumab for the Treatment of Platinum Resistant, Recurrent, or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Platinum-Resistant Ovarian Carcinoma | Refractory Ovarian Carcinoma | Refractory Fallopian Tube... and other conditions

United States
Bay Area Gynecology Oncology

Unknown

Clinical Trial of Intraperitoneal Hyperthermic Chemotherapy (HIPEC/IPHC)

Cervical Cancer | Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cancer | Uterine Cancer | Gastrointestinal Cancers | Mesotheliomas

United States
Rutgers, The State University of New Jersey

Recruiting

Choices About Genetic Testing And Learning Your Risk With Smart Technology (CATALYST)

Breast Cancer | Colorectal Cancer | Ovarian Cancer | Fallopian Tube Cancer | Prostate Cancer | Endometrial Cancer | Pancreas Cancer | Peritoneal Cancer

United States
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Completed

MRI and Cardio-Pulmonary Exercise Testing in Evaluating Exercise Intolerance in Patients With Stage I-III Breast Cancer After Chemotherapy Treatment

Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Healthy Subject

United States
Precision Therapeutics

Terminated

ChemoFx® PRO - A Post-Market Data Collection Study

Cervical Cancer | Uterine Neoplasms | Ovarian Cancer | Fallopian Tube Cancer | Vulvar Cancer | Endometrial Cancer | Vaginal Cancer | Peritoneal Cancer

United States
Boston Scientific Corporation

Completed

Compare Fallopian Tube Cells Collected by Cytuity With Removed Ovarian/Tubal Tissue to Determine Presence of Malignancy (nCYT)

Ovarian Diseases | Ovarian Neoplasms | Fallopian Tube Neoplasms | Peritoneal Neoplasms | Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Carcinoma | Fallopian Tube Adenocarcinoma | High Grade Serous Carcinoma | Ovary Cancer | Adnexal Mass

United States
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

Ovarian Seromucinous Carcinoma | Recurrent Ovarian High Grade Serous Adenocarcinoma | Recurrent Platinum-Resistant Ovarian Carcinoma | Fallopian Tube Mucinous Adenocarcinoma | Recurrent Fallopian Tube Clear Cell Adenocarcinoma | Recurrent Fallopian Tube Endometrioid Adenocarcinoma | Recurrent... and other conditions

United States, Puerto Rico
ImmunoGen, Inc.
GOG Foundation

Recruiting

Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer (GLORIOSA)

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cancer

United States, Korea, Republic of, Spain, Australia, Canada, United Kingdom, Italy, Czechia, Philippines, Israel, Belgium
Shanghai Gynecologic Oncology Group
Fudan University

Not yet recruiting

Survival Effect of Hepato-celiac Lymphadenectomy In Primary or Relapsed Ovarian Cancer

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Primary Peritoneal Carcinoma

China
University of Oklahoma

Terminated

Feasibility Trial of Intraperitoneal Chemotherapy for Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Carcinoma | Uterine Cancer

United States
Turku University Hospital

Recruiting

Overcoming Chemoresistance in Advanced Ovarian Cancer Via Targeting Hypoxia (OVANOX)

Hypoxia | Fallopian Tube Cancer | Epithelial Ovarian Cancer | Peritoneal Carcinoma

Finland
ImmunoVaccine Technologies, Inc. (IMV Inc.)

Completed

Phase 1b Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Peritoneal Cancer

Canada, United States
Krankenhaus Barmherzige Schwestern Linz

Withdrawn

HIPEC After Secondary Cytoreductive Operation in Patients With Platinum-sensitive Recurrence of Ovarian Carcinoma (HIPEC)

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Peritoneal Cancer

Austria
National Cancer Institute (NCI)

Active, not recruiting

Gemcitabine Hydrochloride Alone or With M6620 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Serous Tumor

United States
ImmunoGen, Inc.

Completed

A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression (SORAYA)

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Peritoneal Cancer

United States, Belgium, Spain, Israel, Australia, Ireland, Germany, Italy, Bulgaria, Czechia, Poland
National Cancer Institute (NCI)

Completed

Gefitinib in Treating Patients With Cervical Cancer

Cervical Cancer | Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

United States
Sutro Biopharma, Inc.

Recruiting

Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Cancers

Ovarian Cancer | Fallopian Tube Cancer | Endometrial Cancer | Ovarian Carcinoma | Endometrioid Adenocarcinoma | Ovary Cancer | Primary Peritoneal Carcinoma

United States, Spain
Turku University Hospital

Active, not recruiting

Epithelial Ovarian Cancer- Staging and Response to Chemotherapy Evaluated by PET/CT (Mupet)

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Peritoneal Cancer

Finland
City of Hope Medical Center

Completed

Cyclophosphamide With or Without Celecoxib in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

Fallopian Tube Cancer | Peritoneal Cavity Cancer | Recurrent Ovarian Epithelial Cancer

United States
National Cancer Institute (NCI)
Gynecologic Oncology Group

Completed

Temsirolimus in Treating Patients With Refractory or Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer | Recurrent Ovarian Epithelial Cancer

United States
National Cancer Institute (NCI)

Completed

Eribulin Mesylate in Treating Patients With Recurrent Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer

Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer | Recurrent Ovarian Epithelial Cancer

United States
Floyd & Delores Jones Cancer Institute at Virginia...

Completed

Docetaxel and Carboplatin in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Hypnosedation in Relaxing Patients Undergoing Breast Cancer Surgery

Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Prognostic Stage I Breast Cancer AJCC v8 | Prognostic Stage IA Breast Cancer AJCC v8 | Prognostic Stage IB Breast Cancer AJCC v8 | Anatomic Stage 0 Breast Cancer AJCC v8 | Prognostic...

United States
National Cancer Institute (NCI)

Completed

Combination Chemotherapy and Paclitaxel Plus Trastuzumab in Treating Women With Palpable Breast Cancer That Can Be Removed by Surgery

Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | HER2/Neu Positive

United States, Puerto Rico
Artios Pharma Ltd

Recruiting

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

Ovarian Cancer | Fallopian Tube Cancer | Metastatic Cancer | Advanced Cancer | Primary Peritoneal Cancer

United States, Spain, United Kingdom, France
Celgene
Gynecologic Oncology Group

Completed

VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Primary Peritoneal Cancer

United States
Lee's Pharmaceutical Limited

Unknown

A Clinical Study of Gimatecan in Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer

Ovarian Epithelial Cancer | Fallopian Tube Cancer | Primary Peritoneal Cancer

China
Gynecologic Oncology Group
National Cancer Institute (NCI)

Terminated

Amifostine in Treating Women With Ovarian, Peritoneal, Cervical, Fallopian Tube, Uterine, or Endometrial Cancer

Sarcoma | Cervical Cancer | Ovarian Cancer | Fallopian Tube Cancer | Endometrial Cancer | Neurotoxicity | Primary Peritoneal Cavity Cancer

United States
ARCAGY/ GINECO GROUP
European Organisation for Research and Treatment of Cancer - EORTC; Scherin... and other collaborators

Completed

Caelyx Plus Carboplatin Versus Paclitaxel Plus Carboplatin in Patients With Epithelial Ovarian Cancer in Late Relapse (CALYPSO)

Ovarian Cancer | Fallopian Tube Cancer

France
University of California, San Francisco
Carl Zeiss Meditec AG

Recruiting

Intraoperative Radiation Therapy in Treating Patients With Breast Cancer Undergoing Breast-Conserving Surgery

Stage IA Breast Cancer | Stage IIA Breast Cancer

United States
ImmunoGen, Inc.

Active, not recruiting

Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers (PICCOLO)

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cancer

United States, France, Belgium, Spain, Ireland, Italy, Australia, Canada
AGO Study Group
Cancer Research UK; ARCAGY/ GINECO GROUP; Grupo Español de Investigación en Cáncer... and other collaborators

Completed

Study Comparing Tumor Debulking Surgery Versus Chemotherapy Alone in Recurrent Platinum-Sensitive Ovarian Cancer (DESKTOPIII)

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cavity Cancer

Spain, France, Denmark, Belgium, Germany, Austria, China, Italy, Korea, Republic of, Norway, Sweden, United Kingdom
Warwick Medical School

Unknown

Two Different Schedules of Carboplatin, Paclitaxel, Gemcitabine, and Surgery in Treating Patients With Newly Diagnosed Stage IIIC or Stage IV Primary Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

United Kingdom
Fox Chase Cancer Center
National Cancer Institute (NCI)

Withdrawn

Metformin Hydrochloride, Carboplatin, and Paclitaxel in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Ovarian Serous Cystadenocarcinoma | Recurrent Ovarian Epithelial Cancer | Recurrent Primary Peritoneal Cavity Cancer | Recurrent Ovarian Germ Cell Tumor | Ovarian Papillary Serous Carcinoma | Recurrent Fallopian Tube Cancer

United States
University of Miami
Merck Sharp & Dohme LLC

Terminated

Pembrolizumab, Paclitaxel, and Carboplatin in Patients With Advanced Stage Epithelial Ovarian Cancer (EOC).

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Peritoneum Cancer

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Withdrawn

Vaccine Therapy and OPT-821 or OPT-821 Alone in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer in Complete Remission

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer
Genzyme, a Sanofi Company

Withdrawn

ILX-295501 in Treating Patients With Stage III or Stage IV Ovarian Cancer That Has Not Responded to Previous Treatment

Ovarian Cancer | Fallopian Tube Cancer | Metastatic Cancer | Primary Peritoneal Cavity Cancer

United States
Medical Research Council

Completed

Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Newly Diagnosed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

France, Australia, United Kingdom, Norway, Germany
M.D. Anderson Cancer Center
Millennium Pharmaceuticals, Inc.

Completed

PS-341 Plus Carboplatin in Platinum and Taxane Resistant Recurrent Ovarian Cancer, Primary Peritoneal Cancer, and Fallopian Tube Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cancer

United States
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Ovarian Clear Cell Adenocarcinoma | Ovarian Mucinous Adenocarcinoma | Fallopian Tube... and other conditions

United States
Shenzhen SiBiono GeneTech Co.,Ltd

Unknown

p53 Gene in Treatment of Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer

Ovarian Epithelial Cancer | Fallopian Tube Cancer | Primary Peritoneal Cancer

China

Clinical Trials on Stage IA Fallopian Tube Cancer

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Equatorial Guinea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations